Side effects of GLP-1 after stopping
You are dealing with a symptom and want to know if it is expected.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
The adverse reactions section of a prescribing information describes what happens while the drug is being taken. It is not a description of what happens after you stop, and these labels do not carry a symptom timeline for discontinuation. That is a gap in the source documents rather than something this page can fill by averaging forum reports.
Listed in the prescribing information
Common adverse reactions listed for GLP-1 receptor agonists as a class.
- NauseaMost commonly reported; typically worst after a dose increase.
- DiarrhoeaGastrointestinal effects are the most frequently listed category.
- VomitingReported more often at higher doses.
- ConstipationRelated to slowed gastric emptying.
- Abdominal painListed across the class.
- Injection site reactionsApplies to injectable products only.
- FatigueListed in product labelling.
- HeadacheListed in product labelling.
These products carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Read the full prescribing information for your specific product and discuss it with your prescriber — this summary is not complete and is not a substitute for that document.
Two questions get bundled together here and they are worth separating. One is whether these effects ease after stopping. The other is whether appetite and weight return — which is not an adverse reaction at all, it is the treatment effect ending. Only the first is answered by the list above, and neither is answered with a date. Anything you are experiencing after stopping belongs with your prescriber, who can see what else changed at the same time.
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Mounjaro (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Wegovy (Semaglutide) prescribing information — Novo Nordisk, label revised 30 June 2026, checked 7 August 2026
- Ozempic (Semaglutide) prescribing information — Novo Nordisk, label revised 10 June 2026, checked 7 August 2026
- Rybelsus (Semaglutide) prescribing information — Novo Nordisk, label revised 20 May 2026, checked 7 August 2026
- Saxenda (Liraglutide) prescribing information — Novo Nordisk, label revised 15 June 2026, checked 7 August 2026
- Trulicity (Dulaglutide) prescribing information — Eli Lilly, label revised 25 March 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Related
- GLP-1 side effectsSide effects
- GLP-1 long term side effectsSide effects
- GLP-1 patches side effectsSide effects
- GLP-1 side effects cancerSide effects
- Side effects of GLP-1 shotsSide effects
- Which GLP-1 has the least side effectsSide effects
- GLP-1 side effects redditSide effects
- GLP-1 tirzepatide side effectsSide effects